<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">PI</journal-id><journal-title-group><journal-title>Pharmacy Information</journal-title></journal-title-group><issn pub-type="epub">2160-441X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/PI.2021.105032</article-id><article-id pub-id-type="publisher-id">PI-44910</article-id><article-categories><subj-group subj-group-type="heading"><subject>PI20210500000_59425742.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  儿童免疫性血小板减少症相关机制研究进展及药物评价
  Research Progress and Drug Evaluation of Immunological Thrombocytopenia in Children
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>岳</surname><given-names>登媛</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>梦婷</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>沈</surname><given-names>婷</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>钱</surname><given-names>明霞</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>徐</surname><given-names>柳红</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>胡</surname><given-names>梦娇</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>浙江中医药大学医学技术学院，浙江 杭州</addr-line></aff><aff id="aff4"><addr-line>浙江中医药大学基础医学院，浙江 杭州</addr-line></aff><aff id="aff2"><addr-line>浙江中医药大学公共卫生学院，浙江 杭州</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>30</day><month>08</month><year>2021</year></pub-date><volume>10</volume><issue>05</issue><fpage>252</fpage><lpage>260</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   免疫性血小板减少症是儿童最常见的获得性免疫介导出血性疾病之一，其异质性明显，在儿童中尤其突出，具体发病机制、自然病程、并发症及治疗方案因人而异。随着免疫性血小板减少症(Immune Thrombocytopenic Purpura, ITP)在治疗的研究进展中，儿童ITP的治疗获得了一定突破，一般认为治疗儿童ITP的常见用药包括肾上腺糖皮质激素类药物、丙种球蛋白以及刺激血小板生成类药物等，新型药物以免疫抑制剂及生物制品等，本文探讨了国内外儿童免疫性血小板减少症的流行特征、发病机制及治疗进展，以此展开综述。 Immune thrombocytopenia is one of the most common acquired immune-mediated hemorrhagic diseases in children. Its heterogeneity is obvious, especially prominent in children. The specific pathogenesis, natural course, complications and treatment plan vary from person to person. As immune thrombocytopenia (ITP) in the diagnosis, treatment, the progress of the treatment of ITP in children to obtain a breakthrough, it is generally believed to treat common medication of ITP in children include sugar cortical hormone drugs, gamma globulin and stimulate platelet production drugs, new drugs to immunosuppressants and biological products, etc., This article will review the epidemiological characteristics, pathogenesis and treatment progress of immune thrombocytopenia in children at home and abroad. 
  
 
</p></abstract><kwd-group><kwd>儿童，免疫性血小板减少症，发病机制，药物评价, Child</kwd><kwd> Immune Thrombocytopenia</kwd><kwd> Etiology and Pathogenesis</kwd><kwd> Drug-Evaluation</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>免疫性血小板减少症是儿童最常见的获得性免疫介导出血性疾病之一，其异质性明显，在儿童中尤其突出，具体发病机制、自然病程、并发症及治疗方案因人而异。随着免疫性血小板减少症(Immune Thrombocytopenic Purpura, ITP)在治疗的研究进展中，儿童ITP的治疗获得了一定突破，一般认为治疗儿童ITP的常见用药包括肾上腺糖皮质激素类药物、丙种球蛋白以及刺激血小板生成类药物等，新型药物以免疫抑制剂及生物制品等，本文探讨了国内外儿童免疫性血小板减少症的流行特征、发病机制及治疗进展，以此展开综述。</p></sec><sec id="s2"><title>关键词</title><p>儿童，免疫性血小板减少症，发病机制，药物评价</p></sec><sec id="s3"><title>Research Progress and Drug Evaluation of Immunological Thrombocytopenia in Children<sup> </sup></title><p>Dengyuan Yue<sup>1</sup>, Mengting Chen<sup>2</sup>, Ting Shen<sup>1</sup>, Mingxia Qian<sup>1</sup>, Liuhong Xu<sup>1</sup>, Mengjiao Hu<sup>3*</sup></p><p><sup>1</sup>College of Public Health Medicine, Zhejiang Chinese Medical University, Hangzhou Zhejiang</p><p><sup>2</sup>College of Medical Technology, Zhejiang Chinese Medical University, Hangzhou Zhejiang</p><p><sup>3</sup>College of Basic Medicine, Zhejiang Chinese Medical University, Hangzhou Zhejiang</p><p><img src="//html.hanspub.org/file/2-1710287x5_hanspub.png?20210901092205987" /></p><p>Received: Jul. 26<sup>th</sup>, 2021; accepted: Aug. 22<sup>nd</sup>, 2021; published: Aug. 31<sup>st</sup>, 2021</p><p><img src="//html.hanspub.org/file/2-1710287x6_hanspub.png?20210901092205987" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Immune thrombocytopenia is one of the most common acquired immune-mediated hemorrhagic diseases in children. Its heterogeneity is obvious, especially prominent in children. The specific pathogenesis, natural course, complications and treatment plan vary from person to person. As immune thrombocytopenia (ITP) in the diagnosis, treatment, the progress of the treatment of ITP in children to obtain a breakthrough, it is generally believed to treat common medication of ITP in children include sugar cortical hormone drugs, gamma globulin and stimulate platelet production drugs, new drugs to immunosuppressants and biological products, etc., This article will review the epidemiological characteristics, pathogenesis and treatment progress of immune thrombocytopenia in children at home and abroad.</p><p>Keywords:Child, Immune Thrombocytopenia, Etiology and Pathogenesis, Drug-Evaluation</p><disp-formula id="hanspub.44910-formula20"><graphic xlink:href="//html.hanspub.org/file/2-1710287x7_hanspub.png?20210901092205987"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/2-1710287x8_hanspub.png?20210901092205987" /> <img src="//html.hanspub.org/file/2-1710287x9_hanspub.png?20210901092205987" /></p></sec><sec id="s5"><title>1. 儿童ITP概述</title><sec id="s5_1"><title>1.1. 流行病学特征</title><p>免疫性血小板减少症(ITP)是一种相对常见的儿童疾病，儿童发病率为2.0/(10万人&#183;年)~6.4/(10万人&#183;年)，通常出现在年龄1至10岁儿童之间，发病高峰在5岁左右 [<xref ref-type="bibr" rid="hanspub.44910-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.44910-ref2">2</xref>]。儿童免疫性血小板减少症是一种自限性疾病，大多数患儿可在确诊12个月后恢复正常，仅约20%左右的患儿病程持续1年以上 [<xref ref-type="bibr" rid="hanspub.44910-ref3">3</xref>]。</p></sec><sec id="s5_2"><title>1.2. 发病机制</title><p>ITP传统和新兴疗法的作用机制(见图1)主要通过抑制免疫应答介导的血小板破坏、促进血小板生成以及调节骨髓的微环境。60%~70%的ITP患者可以检测出特异性自身抗体IGG抗体，这些自身抗体(GPIIb/IIIa和GPIb-IX-V等)和血小板膜糖蛋白结合被吞噬破坏(结合方式差异取决于血小板自身抗体的靶点；部分ITP患者没有血小板抗体，可能存在异常的细胞毒性CD8<sup>+</sup> T细胞介导的血小板破坏；患儿上调VLA-4和CX3CR1使T细胞在骨髓中富集，抑制骨髓巨核细胞生成血小板，使外周血小板计数减少 [<xref ref-type="bibr" rid="hanspub.44910-ref4">4</xref>]。ITP涉及的免疫机制十分复杂，儿童发病机制与成人ITP不全相同，儿童大多为急性、自限性 [<xref ref-type="bibr" rid="hanspub.44910-ref5">5</xref>]。</p></sec></sec><sec id="s6"><title>2. 一线治疗</title><p>糖皮质激素、静脉注射免疫球蛋白和抗D免疫球蛋白作为经典的ITP一线治疗方案。成人ITP患者以糖皮质激素为首选治疗，而儿童ITP治疗更倾向于静脉免疫球蛋白治疗方案(见表1)。</p><sec id="s6_1"><title>2.1. 糖皮质激素</title><sec id="s6_1_1"><title>2.1.1. 大剂量地塞米松(HD-DXM)</title><p>Mervat等人纳入20名慢性ITP患儿连续4天接受单剂量24 mg/m<sup>2</sup>地塞米松静脉注射治疗后，在治疗前一天和第五天分别评估血小板计数，90%的患儿出血症状得到有效控制(血小板计数至少增加 ≥ 30 &#215; 10<sup>9</sup>/L)，其中50%的患儿出血症状完全缓解(血小板计数 ≥ 100 &#215; 10<sup>9</sup>/L) [<xref ref-type="bibr" rid="hanspub.44910-ref6">6</xref>]，单疗程HD-DXM可在1~3天内将90%出血症状达到有效控制，证明短期HD-DXM治疗儿童慢性ITP出血失控是一种有效紧急治疗方法，特别是在资源有限的国家。注意地塞米松用药时需同时监测血压、血糖、胃肠道反应等生理指标的变化，预防和治疗感染等副作用。</p></sec><sec id="s6_1_2"><title>2.1.2. 泼尼松/强的松(PDN)</title><p>泼尼松作为一种中效型肾上腺皮质激素，一项临床试验报告了31例ITP患儿接受为期三个月醋酸泼尼松龙治疗后，血小板计数、CD3<sup>+</sup>、CD3<sup>+</sup>CD4<sup>+</sup>/CD3<sup>+</sup>CD8<sup>+</sup>、CD4<sup>+</sup>CD25<sup>+</sup>CD127细胞计数显著升高，患儿初始缓解率为50%~60%，长期缓解率 &lt; 30% [<xref ref-type="bibr" rid="hanspub.44910-ref7">7</xref>]。根据柳叶刀杂志的一项大剂量地塞米松与泼尼松疗效对比的荟萃分析中证实在长期改善血小板计数反应中，标准剂量泼尼松与大剂量地塞米松无统计学差异(P &lt; 0.05)；而对于需要快速增加血小板计数的临床手术中急性免疫性血小板减少症患者，大剂量地塞米松可能优于泼尼松 [<xref ref-type="bibr" rid="hanspub.44910-ref8">8</xref>]。另一项荟萃分析也证明HD-DXM的不良反应事件更少、长期复发率更低 [<xref ref-type="bibr" rid="hanspub.44910-ref9">9</xref>]。因此对于初诊断的ITP患儿首选大剂量地塞米松。</p></sec></sec><sec id="s6_2"><title>2.2. 静脉注射免疫球蛋白(IVIG)</title><p>静脉免疫球蛋白(IVIG)是一种人免疫球蛋白混合的免疫抑制剂，IVIG作用于巨噬细胞表面或树突细胞表面的Fc受体，抑制巨噬细胞的吞噬防止自身血小板被内皮网状系统吞噬，抑制血小板计数水平减少 [<xref ref-type="bibr" rid="hanspub.44910-ref10">10</xref>]，但是不可否认其高昂价格所带来的应用局限 [<xref ref-type="bibr" rid="hanspub.44910-ref11">11</xref>]。Martin等人对34例急性患儿(血小板计数低于20 &#215; 10<sup>9</sup>/L)连续2天以2 g/kg/d和0.6 g/kg/d IVIG剂量予以治疗 [<xref ref-type="bibr" rid="hanspub.44910-ref12">12</xref>]，发现在给药72小时后高剂量组血小板计数增加速度显著高于低剂量组，但大剂量IVIG所带来的副作用也更为明显。在一项303例原发型ITP患儿的随机对照实验中证实单独应用IVIG或IVIG联合激素的疗效均优于单一糖皮质激素疗法 [<xref ref-type="bibr" rid="hanspub.44910-ref13">13</xref>]；参照国际共识，对亟须治疗的出血患儿推荐糖皮质激素联合IVIG。</p></sec><sec id="s6_3"><title>2.3. 抗D免疫球蛋白</title><p>抗D免疫球蛋白治疗机制与IVIG相似，但抗D免疫球蛋白价格显著低于IVIG。一项就儿童急性ITP临床效果的荟萃分析中 [<xref ref-type="bibr" rid="hanspub.44910-ref14">14</xref>]，静脉注射抗-D在改善急性ITP患儿的血小板计数方面与IVIG相似(抗D组和IVIG组在治疗24、72和7天后血小板计数无显著差异(P &gt; 0.05))。另一项就抗D免疫球蛋白与IVIG疗效对比的随机对照实验中 [<xref ref-type="bibr" rid="hanspub.44910-ref15">15</xref>] 证明在最初治疗的72小时内，IVIG疗法较静脉注射抗D的血小板计数增加速率更快。故IVIG优于注射抗D免疫球蛋白在急性ITP患儿治疗中。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Summary of first-line treatment drug</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >一线治疗</th><th align="center" valign="middle" >使用剂量</th><th align="center" valign="middle" >起效时间</th><th align="center" valign="middle" >应用价值</th><th align="center" valign="middle" >适用人群</th><th align="center" valign="middle" >不良反应</th><th align="center" valign="middle" >潜在不足</th><th align="center" valign="middle" ></th></tr></thead><tr><td align="center" valign="middle" >糖皮质激素</td><td align="center" valign="middle" >(2~4 mg/kg) &#215; (5~7) d</td><td align="center" valign="middle" >3~4 d</td><td align="center" valign="middle" >糖皮质激素联合用药方案对大部分患儿有效，可持续用药。</td><td align="center" valign="middle" >初诊断患儿均可</td><td align="center" valign="middle" >免疫抑制、生长缓慢、骨质减少、行为改变、血压升高、食欲增加、胃炎等 [<xref ref-type="bibr" rid="hanspub.44910-ref16">16</xref>] 。</td><td align="center" valign="middle" >长期用药会产生激素相关性副作用；约20%患儿对糖皮质激素无效。</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >静脉注射 丙种球蛋白 (IVIg)</td><td align="center" valign="middle" >400 mg/(kg/d) &#215; (3~5) d； 0.8~1.0 g/(kg/d)静注</td><td align="center" valign="middle" >24~48 h</td><td align="center" valign="middle" >单剂量方案；起效指证迅速，早期血小板提升方面优于激素治疗。IVIg治疗后儿童患慢性ITP风险降低。</td><td align="center" valign="middle" >服药依从性差的患儿(婴幼儿)；重症或伴有严重皮肤黏膜瘀点、瘀斑或伴有活动性出血患者。</td><td align="center" valign="middle" >已知和未知病原体的潜在感染风险。流感样症状，可伴有恶心、呕吐和发热，急性肾损伤，溶血性贫血；超敏反应，无菌性脑膜炎。</td><td align="center" valign="middle" >价格昂贵，作用维持时间短；用药风险高可发生严重副反应。</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >抗D免疫球蛋白 (Anti-D immunoglobulin)</td><td align="center" valign="middle" >75 μg/(kg&#183;d)静注</td><td align="center" valign="middle" >24~48 h</td><td align="center" valign="middle" >患儿须为Rh<sup>+</sup>，且未进行脾切除手术。</td><td align="center" valign="middle" >/</td><td align="center" valign="middle" >同种免疫溶血、肾功能不全和感染 [<xref ref-type="bibr" rid="hanspub.44910-ref17">17</xref>] ；低血压、关节痛、腹部或背部肌痛、瘙痒、发疹。</td><td align="center" valign="middle"  colspan="2"  >类似IVIg</td></tr></tbody></table></table-wrap><p>表1. 一线治疗药物总结</p></sec></sec><sec id="s7"><title>3. 二线治疗(见表2)</title><sec id="s7_1"><title>3.1. 脾切除术</title><p>由于脾切除术具有侵入性、不可逆性、需要终身监测管理的限制不足，故几乎不用于儿童治疗方案中，不予以详细叙述。</p></sec><sec id="s7_2"><title>3.2. 促血小板生成素与血小板受体激动剂rhTPO</title><sec id="s7_2_1"><title>3.2.1. 艾曲波帕</title><p>艾曲波帕在美国和欧盟获得批准可用于≥ 1岁且其他疗法无效的儿童慢性免疫性血小板减少症(ITP)。在一项为期五年的回顾性分析中 [<xref ref-type="bibr" rid="hanspub.44910-ref18">18</xref>] Eltrombopag治疗的23例小儿ITP患者，在治疗后的第2周、4周、3个月和6个月的血小板中位数(PLT)分别为40(4~170) &#215; 10<sup>9</sup>/L，20(4~130) &#215; 10<sup>9</sup>/L，60(4~110) &#215; 10<sup>9</sup>/L和70(18~160) &#215; 10<sup>9</sup>/L均明显高于治疗前。另一项随机对照研究中同样证明对患有持续性或慢性免疫性血小板减少症的儿童，Eltrombopag可有效减少临床上明显出血症状 [<xref ref-type="bibr" rid="hanspub.44910-ref19">19</xref>]。</p></sec><sec id="s7_2_2"><title>3.2.2. 罗米司汀</title><p>罗米司汀(Romiplostim)是美国FDA批准的新药，为Fc融合蛋白(与血小板生成素类药物机制相似)可升高血小板计数，降低ITP患者出血的风险。Vinente等人对三例难治性ITP患儿研究中，观察到在7到28天内患儿可达到缓解，三例患儿有轻微不良反应的发生 [<xref ref-type="bibr" rid="hanspub.44910-ref20">20</xref>]。一项长期研究中，证明接受Romiplostim治疗可增加ITP儿童的血小板计数并维持4年以上，且耐受性良好且无明显毒性 [<xref ref-type="bibr" rid="hanspub.44910-ref21">21</xref>]。过去十多年中罗米司汀一直作为治疗成人ITP的常见疗法，现大量研究表明，其对于慢性难治性儿童ITP患儿也具有一定疗效和安全性，Romiplostim可以被认为是免疫抑制疗法(如Rituximab或脾切除术)的替代治疗方案。</p></sec><sec id="s7_2_3"><title>3.2.3. 重组血小板生成素rhTPO</title><p>重组血小板生成素是由中国仓鼠卵巢细胞表达，在国内首个应用的促血小板生成类药物。一项入组了30例重症ITP患儿 [<xref ref-type="bibr" rid="hanspub.44910-ref22">22</xref>] 中有17例(56.67%)通过rhTPO治疗获得了缓解。另一项在对经一线治疗失败的58例患儿 [<xref ref-type="bibr" rid="hanspub.44910-ref23">23</xref>] 中随机分为两组：DXM治疗(n = 27)和rhTPO + DXM治疗(n = 31)组，在治疗7、14天、1个月和2个月，分别进行评估总体缓解率，结果表明rhTPO + DXM组的总体缓解率均高于DXM治疗组(P &lt; 0.05)，rhTPO联合大剂量DXM可作为目前治疗难治性ITP患儿的一种安全有效的方法。</p></sec></sec><sec id="s7_3"><title>3.3. 小剂量利妥昔单抗</title><p>低剂量利妥昔单抗是一种嵌合单克隆抗体，其靶向正常和恶性B淋巴细胞表面的CD20抗原 [<xref ref-type="bibr" rid="hanspub.44910-ref24">24</xref>]。Wang等人 [<xref ref-type="bibr" rid="hanspub.44910-ref25">25</xref>] 入组了24名患儿接受每周4次375 mg/m<sup>2</sup>利妥昔单抗治疗，结果显示24名患者中有15名(63%)的CR持续了4到30个月，CR率&gt;50％的儿童平均持续13个月，利妥昔单抗可能是治疗慢性免疫性血小板减少性紫癜的有效方法。由于利妥昔单抗的作用机制几乎只影响B细胞，而没有直接影响免疫系统其他细胞(特别是T细胞和浆细胞)的活性，因此与其他药物联合使用有效率更高。在一项20例ITP患者中给予大剂量地塞米松、低剂量利妥昔单抗和环孢素 [<xref ref-type="bibr" rid="hanspub.44910-ref26">26</xref>]，治疗6个月后缓解率为60%，第12个月的无复发生存率为92%，第24个月的无复发生存率为76%，联合使用疗效及预后良好。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Summary of second-line treatment drug</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >二线治疗</th><th align="center" valign="middle" >使用剂量</th><th align="center" valign="middle" >长期反应率</th><th align="center" valign="middle" >应用价值</th><th align="center" valign="middle" >潜在不足</th><th align="center" valign="middle" >不良反应</th></tr></thead><tr><td align="center" valign="middle" >艾曲波帕</td><td align="center" valign="middle" >12.5~50.0 mg/d</td><td align="center" valign="middle" >70%</td><td align="center" valign="middle" >儿童慢性ITP首选治疗。</td><td align="center" valign="middle" >长期应用易出现鼻咽炎和上呼吸道感染；血液和淋巴系统紊乱。</td><td align="center" valign="middle" >头痛、肝功能异常、白内障、血栓形成、骨髓纤维化、铁缺乏 [<xref ref-type="bibr" rid="hanspub.44910-ref27">27</xref>] 。</td></tr><tr><td align="center" valign="middle" >罗米司汀</td><td align="center" valign="middle" >1 μg/kg~10 μg/kg/w，静注</td><td align="center" valign="middle" >37%~91%</td><td align="center" valign="middle" >作为免疫抑制剂类药物的替代疗法治疗慢性难治性ITP患儿。</td><td align="center" valign="middle" >类似艾曲波帕，也存在非致命性不良反应的发生。</td><td align="center" valign="middle" >较少不良反应，偶头晕、恶心、肌痛、四肢痛、腹痛、肩痛、食欲不振及感觉异常等，最严重的不良反应是停药后骨髓网硬蛋白沉积 [<xref ref-type="bibr" rid="hanspub.44910-ref28">28</xref>] 。</td></tr><tr><td align="center" valign="middle" >血小板受体激动剂rhTPO</td><td align="center" valign="middle" >1.0 μg/kg/d，静注</td><td align="center" valign="middle" >65%~90%</td><td align="center" valign="middle" >短期提高血小板计数，安全性好，依从性强。</td><td align="center" valign="middle" >价格昂贵，可能有增加恶性血液病的风险。</td><td align="center" valign="middle" >轻微嗜睡、头痛、阵发性视力缺损、过敏等可逆性反应，可随着药物停止而不良反应逐渐消失。</td></tr><tr><td align="center" valign="middle" >利妥昔单抗</td><td align="center" valign="middle" >375 mg/m<sup>2</sup>/d</td><td align="center" valign="middle" >60%</td><td align="center" valign="middle" >对于难治性ITP起效快，能够显著提高血小板计数 [<xref ref-type="bibr" rid="hanspub.44910-ref29">29</xref>] 。</td><td align="center" valign="middle" >利妥昔单抗的治疗仍是昂贵的，特别是对于难以获得健康资源的患者。另外，高剂量和多次给药可能增加不良反应的风险；存在较高的复发率。</td><td align="center" valign="middle" >不良事件通常较轻且易于控制，主要可能引起低血球蛋白血症、以及某些感染风险的增加轻度过敏反应包括瘙痒、荨麻疹、发冷和发烧 [<xref ref-type="bibr" rid="hanspub.44910-ref30">30</xref>] 。</td></tr></tbody></table></table-wrap><p>表2. 二线药物治疗总结</p></sec></sec><sec id="s8"><title>4. 三线治疗及生物参数预后判断(见表3)</title><sec id="s8_1"><title>4.1. 免疫抑制剂</title><sec id="s8_1_1"><title>4.1.1. 环孢菌素A</title><p>环孢菌素A是近年来用于治疗各种免疫疾病的新型免疫抑制剂类药物，通过抑制钙神经素及白介素-2来控制T淋巴细胞生长。临床发现小剂量环孢菌素即可治疗难治性复发性ITP。在一项回顾性分析中纳入了30例患儿 [<xref ref-type="bibr" rid="hanspub.44910-ref31">31</xref>]，其中17例患儿(57%)达到完全缓解状态，研究中发现环孢菌素A最常见副反应是多毛症。在另一项回顾性研究中 [<xref ref-type="bibr" rid="hanspub.44910-ref32">32</xref>]，证明口服环孢菌素A可作为一种额外的治疗手段以避免脾切除术和长期使用皮质类固醇激素所带来的不良反应。</p></sec><sec id="s8_1_2"><title>4.1.2. 达那唑</title><p>达那唑为雄激素17a-乙炔睾丸酮的衍生物，研究表明输注达那唑后抗体IgG的Fc受体与单核细胞结合位点数量减少与临床缓解呈正相关 [<xref ref-type="bibr" rid="hanspub.44910-ref33">33</xref>]，因此降低Fc受体在巨噬细胞表面的表达水平，可降低血小板损伤程度，增加血小板水平。蔡艳 [<xref ref-type="bibr" rid="hanspub.44910-ref34">34</xref>] 对31例ITP患者给予达那唑200 mg/d，疗程3个月，根据前三个月临床检验所得患者治疗前、后的血小板数均有所增加(P &lt; 0.001)，临床总有效率93%，证实达那唑能有效改善临床症状，稳定血小板计数，且无明显副作用，耐受性良好。</p></sec><sec id="s8_1_3"><title>4.1.3. 霉酚酸酯(吗替麦考酚酯)</title><p>霉酚酸酯是一种有机化合物，能够特异性地抑制淋巴细胞嘌呤合成次黄嘌呤核苷酸脱氢酶的活性进而抑制T、B淋巴细胞增殖。一项前瞻性研究报告了9例慢性ITP患儿经霉酚酸酯联合皮质激素治疗后均到达完全缓解的水平 [<xref ref-type="bibr" rid="hanspub.44910-ref35">35</xref>]，霉酚酸酯可作为一种辅助免疫抑制剂联合皮质类固醇激素用于儿童慢性自身免疫性血细胞减少症治疗。</p></sec><sec id="s8_1_4"><title>4.1.4. 长春新碱</title><p>长春新碱(Vincristine)是一种治疗免疫性血小板减少症的新药，作用于Fc受体(FcR)介导抗原呈递和血小板清除，在患儿巨噬细胞中建立了一种带有抗CD41单抗的新型血小板输送系统(CD41-VCR-PLT, CD41-VLP)。虽然在替代脾切除术方面长春新碱相较于其他免疫抑制剂不具备明显优势性，但在既往病例分析中，长春新碱可以提高患儿依从性，且因其较好安全性和低成本被保留在患儿ITP治疗中。</p></sec></sec><sec id="s8_2"><title>4.2. 低剂量地西他滨(去甲基化药物)</title><p>地西他滨是一种特定的DNA甲基化转移酶抑制剂，可逆转DNA甲基化并激活肿瘤抑制基因的沉默和失活，在ITP患儿中证实了低剂量地西他滨显著增加患者体外培养物中成熟多倍体巨核细胞的数量 [<xref ref-type="bibr" rid="hanspub.44910-ref36">36</xref>]，增强肿瘤坏死因子相关的凋亡诱导配体的表达，可以促进健康对照组和ITP组中巨核细胞的成熟和血小板生成。</p></sec><sec id="s8_3"><title>4.3. 阿托伐他汀</title><p>阿托伐他汀是一种合成的3-羟基-3-甲基戊二酰辅酶A还原酶抑制剂，常用于血脂异常及相关血管异常患者 [<xref ref-type="bibr" rid="hanspub.44910-ref37">37</xref>] [<xref ref-type="bibr" rid="hanspub.44910-ref38">38</xref>]。他汀类药物，如洛伐他汀、阿托伐他汀、普伐他汀和辛伐他汀，经NOS刺激后可以提高NO/O2<sup>−</sup>浓度比值，从而提高NO在内皮细胞中的生物利用度 [<xref ref-type="bibr" rid="hanspub.44910-ref39">39</xref>]。袁孔等人证实阿托伐他汀通过下调p38 MAPK途径和上调Akt途径在数量和功能上改善源自糖皮质激素抵抗性ITP患者的BM EPC [<xref ref-type="bibr" rid="hanspub.44910-ref40">40</xref>]，增强骨髓内皮细胞功能。</p></sec><sec id="s8_4"><title>4.4. 生物参数预后判断</title><p>近年来对免疫球蛋白疗法有反应的ITP患儿是否会在未经治疗下出现自限性病程，利用生物学参数分析进行预估判断被国际中进行广泛研究。而对于少数转归为慢性难治性ITP的患儿也可以通过将生物遗传免疫参数评分结合临床数据来提高ITP疾病病程判断和免疫球蛋白治疗后续预测的准确性。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Summary of third-line treatment drug</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >三线治疗</th><th align="center" valign="middle" >使用剂量</th><th align="center" valign="middle" >长期反应率</th><th align="center" valign="middle" >应用价值</th><th align="center" valign="middle" >潜在不足</th><th align="center" valign="middle" >不良反应</th></tr></thead><tr><td align="center" valign="middle" >环孢菌素A [<xref ref-type="bibr" rid="hanspub.44910-ref31">31</xref>] [<xref ref-type="bibr" rid="hanspub.44910-ref32">32</xref>] [<xref ref-type="bibr" rid="hanspub.44910-ref41">41</xref>]</td><td align="center" valign="middle" >2.4~7.5 mg/kg/d</td><td align="center" valign="middle" >57%</td><td align="center" valign="middle" >强效的、毒性小的，一个较理想的免疫抑制剂。</td><td align="center" valign="middle" >价格昂贵，不良反应相对其他新型治疗药物较多。</td><td align="center" valign="middle" >肾毒性反应、肝功能异多毛症、恶心、头痛、胃肠不适等。</td></tr><tr><td align="center" valign="middle" >霉酚酸酯 [<xref ref-type="bibr" rid="hanspub.44910-ref35">35</xref>]</td><td align="center" valign="middle" >1.5~2.0 g/d，疗程为2至4个月</td><td align="center" valign="middle" >80%</td><td align="center" valign="middle" >可以快速提高血小板计数水平响应率高，与皮质激素联合应用具有良好的前景。</td><td align="center" valign="middle" >药物安全性尚未明确，还需展开大样本的研究加以验证；长期使用可能增加肿瘤的机会。</td><td align="center" valign="middle" >不同程度胃肠道反应。</td></tr><tr><td align="center" valign="middle" >长春新碱 [<xref ref-type="bibr" rid="hanspub.44910-ref42">42</xref>]</td><td align="center" valign="middle" >1~1.5 mg/m<sup>2</sup>，每周一次，缓慢静滴，4~6次</td><td align="center" valign="middle" >10%~75%</td><td align="center" valign="middle" >脾切除术的替代疗法，价格低廉，耐受性好。</td><td align="center" valign="middle" >升高血小板速度缓慢，单独应用效果不理想。</td><td align="center" valign="middle" >易出现周围神经炎、以及消化道反应如食欲下降、恶心、呕吐、腹泻等。</td></tr><tr><td align="center" valign="middle" >达那唑 [<xref ref-type="bibr" rid="hanspub.44910-ref33">33</xref>] [<xref ref-type="bibr" rid="hanspub.44910-ref34">34</xref>] [<xref ref-type="bibr" rid="hanspub.44910-ref43">43</xref>]</td><td align="center" valign="middle" >10~15 mg/(kg&#183;d)，分2~3次口服</td><td align="center" valign="middle" >67%</td><td align="center" valign="middle" >ITP临床疗效满意度高，可有效提高患儿血小板数量，与皮质激素药物联合使用可减少长期使用皮质激素所带来的不良反应。</td><td align="center" valign="middle" >长期毒性还待大量临床试验研究发现。</td><td align="center" valign="middle" >肝酶升高，肝酶升高是最常见的副作用以及雄激素效应、下肢水肿、体重增加，症状与用药剂量有关。</td></tr><tr><td align="center" valign="middle" >低剂量地西他滨 [<xref ref-type="bibr" rid="hanspub.44910-ref36">36</xref>] [<xref ref-type="bibr" rid="hanspub.44910-ref44">44</xref>]</td><td align="center" valign="middle" >3.5 mg/m<sup>2</sup>每周连续三天静脉注射</td><td align="center" valign="middle" >66.7%</td><td align="center" valign="middle" >可以迅速控制临床出血症状；安全、有效的提高ITP患者的血小板水平。</td><td align="center" valign="middle" >安全性缺乏临床试验证实，价格昂贵。</td><td align="center" valign="middle" >长期服用引起胃肠负担，如恶心、呕吐、腹泻症状，肝肾功能不全者慎用。</td></tr><tr><td align="center" valign="middle" >阿托伐他汀 [<xref ref-type="bibr" rid="hanspub.44910-ref39">39</xref>] [<xref ref-type="bibr" rid="hanspub.44910-ref40">40</xref>]</td><td align="center" valign="middle" >20 mg/d</td><td align="center" valign="middle" >69%</td><td align="center" valign="middle" >阿托伐他汀对皮质类固醇抵抗性ITP患者安全有效。</td><td align="center" valign="middle" >/</td><td align="center" valign="middle" >仅少量患者会出现严重不良反应，常见肌肉疼痛、消化道反应。</td></tr></tbody></table></table-wrap><p>表3. 三线药物治疗总结</p><p>图1. 儿童ITP治疗药物机制示意图</p></sec></sec><sec id="s9"><title>5. 总结与展望</title><p>在ITP治疗新时代下，对于儿童来说理想的药物与剂量应同时具备临床效果好、长期预后缓解率高、不良反应少、价格合理等特点，对于新诊断患儿的初始治疗中，我们首先要采取大剂量类固醇激素进行广泛临床应用；考虑到糖皮质激素所产生的后续预后不佳及长期缓解率低等情况，对于儿童精确的特异性诊断与开发有效的联合治疗同样重要，成功的联合疗法如TPO药剂和具有抑制血小板破坏作用机制的药物；既往大量临床实践表明将艾曲波帕作为治疗慢性难治性ITP患儿(激素耐药型)的首选疗法，利妥昔单抗是治疗慢性免疫性血小板减少性紫癜的有效方法。新型分子靶向药物的治疗选择较多，普遍存在起效快、预后良好但价格昂贵、具有潜在肝肾毒副作用仍需在未来展开大样本量的研究；对于慢性难治性患儿，可将生物参数分层与临床表现相结合进行疾病预后病程判断，临床医师应结合儿童ITP个体异质性、综合考虑获益风险比提供最佳个体方案。</p></sec><sec id="s10"><title>文章引用</title><p>岳登媛,陈梦婷,沈 婷,钱明霞,徐柳红,胡梦娇. 儿童免疫性血小板减少症相关机制研究进展及药物评价Research Progress and Drug Evaluation of Immunological Thrombocytopenia in Children[J]. 药物资讯, 2021, 10(05): 252-260. https://doi.org/10.12677/PI.2021.105032</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44910-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Rodeghiero, F., Stasi, R., Gernsheimer, T., Michel, M., Provan, D., Arnold, D.M., et al. (2009) Standardization of Ter-minology, Definitions and Outcome Criteria in Immune Thrombocytopenic Purpura of Adults and Children: Report from an International Working Group. Blood, 113, 2386-2393. &lt;br&gt;https://doi.org/10.1182/blood-2008-07-162503</mixed-citation></ref><ref id="hanspub.44910-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Cines, D.B. and Blanchette, V.S. (2002) Immune Thrombo-cytopenic Purpura. The New England Journal of Medicine, 346, 995-1008. &lt;br&gt;https://doi.org/10.1056/NEJMra010501</mixed-citation></ref><ref id="hanspub.44910-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">国家卫生健康委. 儿童原发性免疫性血小板减少症诊疗规范(2019年版) [J]. 全科医学临床与教育, 2019, 17(12): 1059-1062.</mixed-citation></ref><ref id="hanspub.44910-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Neunert, C., Lim, W., Crowther, M., Cohen, A., Solberg Jr., L. and Crowther, M.A. (2011) The American Society of Hematology 2011 Evidence-Based Practice Guideline for Immune Thrombocytopenia. Blood, 117, 4190-4207.  
&lt;br&gt;https://doi.org/10.1182/blood-2010-08-302984</mixed-citation></ref><ref id="hanspub.44910-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">谢幸娟, 陈振萍. 儿童免疫性血小板减少症发病机制研究进展[J]. 中国实用儿科杂志, 2021; 36(2): 90-94.</mixed-citation></ref><ref id="hanspub.44910-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Youssef, M.A.M., Salah Eldeen, E., Elsayh, K.I., Taha, S.F. and Abo-Elela, M.G.M. (2019) High Dose Dexamethasone as an Alternative Rescue Therapy for Active Bleeding in Children with Chronic ITP: Clinical and Immunological Effects. Platelets, 30, 886-892. &lt;br&gt;https://doi.org/10.1080/09537104.2018.1530347</mixed-citation></ref><ref id="hanspub.44910-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Portielje, J.E., Westendorp, R.G., Kluin-Nelemans, H.C. and Brand, A. (2001) Morbidity and Mortality in Adults with Idiopathic Thrombocytopenic Purpura. Blood, 97, 2549-2554. &lt;br&gt;https://doi.org/10.1182/blood.V97.9.2549</mixed-citation></ref><ref id="hanspub.44910-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Mithoowani, S., Gregory-Miller, K., Goy, J., Miller, M.C., Wang, G., Noroozi, N., et al. (2016) High-Dose Dexamethasone Compared with Prednisone for Previously Untreated Primary Immune Thrombocytopenia: A Systematic Review and Meta-Analysis. The Lancet Haematology, 3, e489-e496. &lt;br&gt;https://doi.org/10.1016/S2352-3026(16)30109-0</mixed-citation></ref><ref id="hanspub.44910-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Arai, Y., Matsui, H., Jo, T., Kondo, T. and Takaori-Kondo, A. (2017) Efficacy of Dexamethasone for Acute Primary Immune Thrombocytopenia Compared to Prednisolone: A Sys-tematic Review and Meta-Analysis. TH Open, 1, e73-e81.  
&lt;br&gt;https://doi.org/10.1055/s-0037-1604168</mixed-citation></ref><ref id="hanspub.44910-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">王丽媛, 刘亢亢, 储金华, 杨林海, 谢志伟, 张坤龙, 等. 儿童免疫性血小板减少症病程慢性化影响因素的研究[J]. 中国实验血液学杂志, 2021, 29(3): 881-886.</mixed-citation></ref><ref id="hanspub.44910-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Balch, A., Wilkes, J., Thorell, E., Pavia, A., Sherwin, C.M.T. and Enioutina, E.Y. (2019) Changing Trends in IVIG Use in Pediatric Patients: A Retrospective Review of Practices in a Network of Major USA Pediatric Hospitals. International Im-munopharmacology, 76, Article ID: 105868. &lt;br&gt;https://doi.org/10.1016/j.intimp.2019.105868</mixed-citation></ref><ref id="hanspub.44910-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Benesch, M., Kerbl, R., Lackner, H., Berghold, A., Schwinger, W., Triebl-Roth, K., et al. (2003) Low-Dose versus High-Dose Im-munoglobulin for Primary Treatment of Acute Immune Thrombocytopenic Purpura in Children: Results of a Prospective, Randomized Single-Center Trial. Journal of Pediatric Hematology/Oncology, 25, 797-800.  
&lt;br&gt;https://doi.org/10.1097/00043426-200310000-00011</mixed-citation></ref><ref id="hanspub.44910-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">李蓉蔚, 付荣凤, 陈云飞, 刘葳, 薛峰, 李慧媛, 等. 原发免疫性血小板减少症住院患儿临床分析[J]. 中国实验血液学杂志, 2021, 29(2): 574-580.</mixed-citation></ref><ref id="hanspub.44910-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">覃薇, 黄少玲, 李婷婷. 抗-D免疫球蛋白治疗儿童免疫性血小板减少症疗效的Meta分析[J]. 中国当代儿科杂志, 2017, 19(10): 1070-1076.</mixed-citation></ref><ref id="hanspub.44910-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Shahgholi, E., Vosough, P., Sotoudeh, K., Arjomandi, K., Ansari, S., Salehi, S., et al. (2008) Intrave-nous Immune Globulin versus Intravenous Anti-D Immune Globulin for the Treatment of Acute Immune Thrombocyto-penic Purpura. Indian Journal of Pediatrics, 75, 1231-1235. &lt;br&gt;https://doi.org/10.1007/s12098-008-0243-y</mixed-citation></ref><ref id="hanspub.44910-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Oray, M., Abu Samra, K., Ebrahimiadib, N., Meese, H. and Foster, C.S. (2016) Long-Term Side Effects of Glucocorticoids. Expert Opinion on Drug Safety, 15, 457-465. &lt;br&gt;https://doi.org/10.1517/14740338.2016.1140743</mixed-citation></ref><ref id="hanspub.44910-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Despotovic, J.M., Lambert, M.P., Herman, J.H., Gernsheimer, T.B., McCrae, K.R., Tarantino, M.D., et al. (2012) RhIG for the Treatment of Immune Thrombocytopenia: Consensus and Controversy (CME). Transfusion, 52, 1126-1136.  
&lt;br&gt;https://doi.org/10.1111/j.1537-2995.2011.03384.x</mixed-citation></ref><ref id="hanspub.44910-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">黄月婷, 刘晓帆, 陈云飞, 付荣凤, 刘葳, 薛峰, 等. 艾曲泊帕治疗儿童原发免疫性血小板减少症23例临床观察[J]. 中华血液学杂志, 2019, 40(12): 1031-1034.</mixed-citation></ref><ref id="hanspub.44910-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Bussel, J.B., de Miguel, P.G., Despotovic, J.M., Grainger, J.D., Sevilla, J., Blanchette, V.S., et al. (2015) Eltrombopag for the Treatment of Children with Persistent and Chronic Immune Thrombocytopenia (PETIT): A Randomised, Multicentre, Placebo-Controlled Study. The Lancet Haematology, 2, e315-e325.  
&lt;br&gt;https://doi.org/10.1016/S2352-3026(15)00114-3</mixed-citation></ref><ref id="hanspub.44910-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Escudero Vilaplana, V., Aragonés, J.H., Fernán-dez-Llamazares, C.M., Bieler, C.B., Rodríguez, S.M. and Sáez, M.S. (2012) Use of Romiplostim for Primary Immune Thrombocytopenia in Children. Pediatric Hematology and Oncology, 29, 197-205. &lt;br&gt;https://doi.org/10.3109/08880018.2011.629401</mixed-citation></ref><ref id="hanspub.44910-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Bussel, J.B., Hsieh, L., Buchanan, G.R., Stine, K., Kalpatthi, R., Gnarra, D.J., et al. (2015) Long-Term Use of the Thrombopoietin-Mimetic Romiplostim in Children with Severe Chronic Immune Thrombocytopenia (ITP). Pediatric Blood &amp; Cancer, 62, 208-213. &lt;br&gt;https://doi.org/10.1002/pbc.25136</mixed-citation></ref><ref id="hanspub.44910-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">黄月婷, 刘晓帆, 薛峰, 陈云飞, 刘葳, 付荣凤, 等. 重组人血小板生成素治疗41例儿童原发免疫性血小板减少症的疗效及安全性[J]. 中华血液学杂志, 2015, 36(6): 511-514.</mixed-citation></ref><ref id="hanspub.44910-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">卢园园, 管娜, 孟庆红, 李明磊, 刘云云, 王莹. rhTPO联合大剂量地塞米松治疗儿童难治性免疫性血小板减少症的临床分析[J]. 中国当代儿科杂志, 2018, 20(7): 534-537.</mixed-citation></ref><ref id="hanspub.44910-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">刘亚璐, 宋玉琴, 朱军. PD-1通路抑制剂在淋巴瘤临床治疗中的研究进展[J]. 中华血液学杂志, 2016, 37(9): 829-832.</mixed-citation></ref><ref id="hanspub.44910-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Wang, J., Wiley, J.M., Luddy, R., Green-berg, J., Feuerstein, M.A. and Bussel, J.B. (2005) Chronic Immune Thrombocytopenic Purpura in Children: Assessment of Rituximab Treatment. The Journal of Pediatrics, 146, 217-221.  
&lt;br&gt;https://doi.org/10.1016/j.jpeds.2004.09.004</mixed-citation></ref><ref id="hanspub.44910-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Choi, P.Y., Roncolato, F., Badoux, X., Ramanathan, S., Ho, S.J. and Chong, B.H. (2015) A Novel Triple Therapy for ITP Using High-Dose Dexamethasone, Low-Dose Rituximab, and Cyclosporine (TT4). Blood, 126, 500-503.  
&lt;br&gt;https://doi.org/10.1182/blood-2015-03-631937</mixed-citation></ref><ref id="hanspub.44910-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">牛子冉, 左玮, 邹羽真, 梅丹, 赵蕾蕾, 张波. 艾曲泊帕治疗儿童慢性免疫性血小板减少症的临床效果[J]. 临床药物治疗杂志, 2020, 18(7): 62-66.</mixed-citation></ref><ref id="hanspub.44910-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">冯永, 董志兴, 左一红, 李明坤. 治疗慢性免疫性血小板减少症新药罗米司汀[J]. 中国药师, 2009, 12(7): 965-966.</mixed-citation></ref><ref id="hanspub.44910-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">桑宝华. 利妥昔单抗对儿童难治性ITP的疗效观察[J]. 世界最新医学信息文摘, 2019, 19(11): 109.</mixed-citation></ref><ref id="hanspub.44910-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Liang, Y., Zhang, L., Gao, J., Hu, D. and Ai, Y. (2012) Rituximab for Children with Immune Thrombocytopenia: A Systematic Review. PLoS ONE, 7, e36698. &lt;br&gt;https://doi.org/10.1371/journal.pone.0036698</mixed-citation></ref><ref id="hanspub.44910-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Liu, A.P., Cheuk, D.K., Lee, A.H., Lee, P.P., Chiang, A.K., Ha, S.Y., et al. (2016) Cyclosporin A for Persistent or Chronic Immune Thrombocytopenia in Children. Annals of Hematology, 95, 1881-1886.  
&lt;br&gt;https://doi.org/10.1007/s00277-016-2791-y</mixed-citation></ref><ref id="hanspub.44910-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Gesundheit, B., Cividalli, G., Freeman, A., Yatziv, S., Koren, G. and Baruchel, S. (2001) Cyclosporin A in the Treatment of Refractory Immune Thrombocytopenia Purpura in Children. European Journal of Haematology, 66, 347-351.  
&lt;br&gt;https://doi.org/10.1034/j.1600-0609.2001.066005347.x</mixed-citation></ref><ref id="hanspub.44910-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Schreiber, A.D., Chien, P., Tomaski, A. and Cines, D.B. (1987) Effect of Danazol in Immune Thrombocytopenic Purpura. The New England Journal of Medicine, 316, 503-508. &lt;br&gt;https://doi.org/10.1056/NEJM198702263160903</mixed-citation></ref><ref id="hanspub.44910-ref34"><label>34</label><mixed-citation publication-type="other" xlink:type="simple">蔡艳. 达那唑对ITP患者血小板数量的影响[J]. 实用药物与临床, 2012, 15(2): 86-87.</mixed-citation></ref><ref id="hanspub.44910-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Panigrahi, A., Clark, A., Myers, J. and Raj, A. (2017) A Novel Immuno-modulatory Treatment Involving Mycophenolate Mofetil and Corticosteroids for Pediatric Autoimmune Cytopenias. Pe-diatric Blood &amp; Cancer, 64, 287-293.  
&lt;br&gt;https://doi.org/10.1002/pbc.26210</mixed-citation></ref><ref id="hanspub.44910-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Zhou, H., Hou, Y., Liu, X., Qiu, J., Feng, Q., Wang, Y., et al. (2015) Low-Dose Decitabine Promotes Megakaryocyte Maturation and Platelet Production in Healthy Controls and Immune Thrombocytopenia. Thrombosis and Haemostasis, 113, 1021-1034. &lt;br&gt;https://doi.org/10.1160/TH14-04-0342</mixed-citation></ref><ref id="hanspub.44910-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Vaughan, C.J., Murphy, M.B. and Buckley, B.M. (1996) Statins Do More than Just Lower Cholesterol. Lancet, 348, 1079-1082. &lt;br&gt;https://doi.org/10.1016/S0140-6736(96)05190-2</mixed-citation></ref><ref id="hanspub.44910-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Li, D.W., Li, J.H., Wang, Y.D. and Li, G.R. (2015) Atorvastatin Protects Endothelial Colony-Forming Cells against H2O2-Induced Oxidative Damage by Regulating the Ex-pression of Annexin A2. Molecular Medicine Reports, 12, 7941-7948. &lt;br&gt;https://doi.org/10.3892/mmr.2015.4440</mixed-citation></ref><ref id="hanspub.44910-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Dobrucki, L.W., Kalinowski, L., Dobrucki, I.T. and Malinski, T. (2001) Statin-Stimulated Nitric Oxide Release from Endothelium. Medical Science Monitor, 7, 622-627.</mixed-citation></ref><ref id="hanspub.44910-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Kong, Y., Cao, X.N., Zhang, X.H., Shi, M.M., Lai, Y.Y., Wang, Y., et al. (2018) Atorvastatin Enhances Bone Marrow Endothelial Cell Function in Corticosteroid-Resistant Immune Thrombocytopenia Patients. Blood, 131, 1219-1233.  
&lt;br&gt;https://doi.org/10.1182/blood-2017-09-807248</mixed-citation></ref><ref id="hanspub.44910-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">潘月芬, 方遒, 吴霞雯. 免疫抑制剂联合应用治疗慢性难治性ITP效果分析[J]. 实用药物与临床, 2013, 16(6): 487-489.</mixed-citation></ref><ref id="hanspub.44910-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">杨青, 宋元华, 吕瑜, 宋春艳, 张翼宇. 免疫抑制剂治疗儿童慢性免疫性血小板减少症的临床研究[J]. 中国医刊 2021, 56(2): 209-212.</mixed-citation></ref><ref id="hanspub.44910-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">董中明, 周朝阳, 李培斌, 杨国彪. 成人原发免疫性血小板减少症二线药物应用[J]. 大理大学学报, 2019, 4(2): 44-48.</mixed-citation></ref><ref id="hanspub.44910-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Tang, Y., Chen, J., Liu, Q., Chu, T., Pan, T., Liang, J., et al. (2021) Low-Dose Decitabine for Refractory Prolonged Isolated Thrombocytopenia after HCT: A Randomized Multicenter Trial. Blood Advances, 5, 1250-1258.</mixed-citation></ref></ref-list></back></article>